Surrozen, Inc.
SRZN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001824893
In the last 90 days, Surrozen, Inc. insiders filed 0 open-market purchases and 1 sale; 70 institutions reported holding it in 13F filings for Q2 2026, worth $314.5M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Surrozen, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +1 vs. Q3 2024
- Shares held
- 2.47M
- +338.8K (+15.9%) vs. Q3 2024
- Total value
- $35.4M
- +$9.95M (+39.1%) vs. Q3 2024
- New holders
- 4
- 5 more added
- Sold out
- 3
- 5 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 70 | $314.5M |
| Q1 2026 | 59 | $314.2M |
| Q4 2025 | 55 | $195.1M |
| Q3 2025 | 36 | $81.7M |
| Q2 2025 | 31 | $53.9M |
| Q1 2025 | 30 | $63.5M |
| Q4 2024 | 24 | $35.4M |
| Q3 2024 | 23 | $25.5M |
| Q2 2024 | 21 | $23.1M |
| Q1 2024 | 16 | $15.0M |
| Q4 2023 | 17 | $9.78M |
| Q3 2023 | 25 | $7.90M |
| Q2 2023 | 22 | $8.62M |
| Q1 2023 | 23 | $9.91M |
| Q4 2022 | 26 | $9.36M |
| Q3 2022 | 27 | $44.1M |
| Q2 2022 | 24 | $63.1M |
| Q1 2022 | 30 | $67.4M |
| Q4 2021 | 32 | $153.5M |
| Q3 2021 | 29 | $150.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Surrozen, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 6 | $86 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 16 | $230 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 32 | $459 | 0.00% | +32 | New |
| Wolverine Asset Management LLC | 281 | $4.03K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 283 | $4.06K | 0.00% | −172−37.8% | Reduced |
| BlackRock, Inc. | 8,247 | $118.3K | 0.00% | +36+0.4% | Added |
| Alyeska Investment Group, L.P. | 10,188 | $146.2K | 0.00% | −10,188−50.0% | Reduced |
| Renaissance Technologies LLC | 13,526 | $194.1K | 0.00% | −300−2.2% | Reduced |
| Price T Rowe Associates Inc | 21,715 | $312.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 22,391 | $321.4K | 0.00% | +4,630+26.1% | Added |
| Morgan Stanley | 34,764 | $498.9K | 0.00% | −447−1.3% | Reduced |
| Trustees of Columbia University in the City of New York | 47,930 | $687.8K | 0.11% | +47,930 | New |
| Board of Trustees of The Leland Stanford Junior University | 52,130 | $748.1K | 0.06% | 00.0% | Unchanged |
| ArrowMark Colorado Holdings LLC | 55,123 | $791.0K | 0.01% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 64,653 | $927.8K | 0.00% | +64,653 | New |
| Vanguard Group Inc | 65,135 | $934.7K | 0.00% | 00.0% | Unchanged |
| Armistice Capital, LLC | 75,694 | $1.09M | 0.03% | −63,306−45.5% | Reduced |
| Euclidean Capital LLC | 87,696 | $1.26M | 0.17% | 00.0% | Unchanged |
| Regents of the University of California | 133,207 | $1.91M | 0.59% | +133,207 | New |
| Stonepine Capital Management, LLC | 137,200 | $1.97M | 1.59% | +27,200+24.7% | Added |
| Nantahala Capital Management, LLC | 196,023 | $2.81M | 0.20% | +8,817+4.7% | Added |
| Ra Capital Management, L.P. | 282,580 | $4.06M | 0.05% | 00.0% | Unchanged |
| StemPoint Capital LP | 350,573 | $5.03M | 1.26% | +167,655+91.7% | Added |
| The Column Group LLC | 810,088 | $11.6M | 20.85% | 00.0% | Unchanged |
| Heights Capital Management, Inc | 0 | $0 | 0.00% | −29,999−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −10,930−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |